Press Releases
Details on the timetable of the simplified tender offer on North Atlantic Energies shares
Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to
Details on the timetable of the simplified tender offer on North Atlantic Energies shares
Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to
Details on the timetable of the simplified tender offer on North Atlantic Energies shares
Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to
Details on the timetable of the simplified tender offer on North Atlantic Energies shares
Paris, Jan. 30, 2026 (GLOBE NEWSWIRE) — NORTH ATLANTIC ENERGIES Details on the timetable of the simplified tender offer on North Atlantic Energies shares Paris, FRANCE – January 30, 2026 – North Atlantic France SAS (“North Atlantic France”) refers to
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease
Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis
Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential. Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease